Christa E Nath1, Judith Trotman2,3, Campbell Tiley4,5, Peter Presgrave6,7, Douglas Joshua3,8, Ian Kerridge3,9, Yiu Lam Kwan2, Howard Gurney3,9, Andrew J McLachlan2,3, John W Earl1,3, Ian Nivison-Smith10, Lihua Zeng1, Peter J Shaw1,3. 1. The Children's Hospital at Westmead, Hawkesbury Rd, Westmead, 2145. 2. Concord Hospital, Hospital Road, Concord, NSW, 2139. 3. University of Sydney, Sydney, NSW, 2006. 4. Gosford Hospital, Holden St, Gosford, NSW, 2250. 5. University of Newcastle, University Dr, Callaghan, NSW, 2308. 6. Wollongong Hospital, Loftus St, Wollongong, NSW, 2500. 7. University of Wollongong, Northfields Ave, Wollongong, NSW, 2522. 8. Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050. 9. Westmead Hospital, Hawkesbury Rd, Westmead, NSW, 2145. 10. Australasian Bone Marrow Transplant Recipient Registry, 370 Victoria Street, Darlinghurst, NSW, 2010, Australia.
Abstract
AIM: High dose melphalan (HDM) and autologous stem cell transplantation (ASCT) retains a central role in the treatment of myeloma. The aim of this study was to determine whether HDM exposure (area under the concentration vs. time curve, AUC), is significantly associated with transplant outcomes. METHODS: Melphalan concentrations were measured in six to 11 plasma samples collected after HDM (median 192 mg m(-) (2) ) to determine melphalan AUC for a total of 114 patients. Binary logistic regression was used to assess whether melphalan AUC was associated with severe (≥ grade 3) oral mucositis. Multivariate Cox regression was used to assess whether melphalan AUC was significantly associated with time to progression, progression-free survival and overall survival (OS). RESULTS: Melphalan AUC ranged from 4.9 to 24.6 mg l(-1) h, median 12.84 mg l(-1) h. Melphalan AUC above the median was a risk factor for severe mucositis (HR 1.21, 95% CI 1.06, 1.38, P = 0.004) but was also associated with significantly improved overall survival (OS) (HR 0.40, 95% CI 0.20, 0.81, P = 0.001), with an estimated median survival of 8.50 years vs. 5.38 years for high vs. low AUC groups. Multivariate analysis did not identify melphalan AUC as being significantly associated with time to progression or progression-free survival. CONCLUSIONS: This large scale pharmacodynamic analysis of HDM demonstrates that high melphalan exposure is associated with improved survival, with an acceptable increase in transplant toxicity. These results suggest studies targeting a higher AUC are warranted in patients undergoing HDM and ASCT for myeloma.
AIM: High dose melphalan (HDM) and autologous stem cell transplantation (ASCT) retains a central role in the treatment of myeloma. The aim of this study was to determine whether HDM exposure (area under the concentration vs. time curve, AUC), is significantly associated with transplant outcomes. METHODS:Melphalan concentrations were measured in six to 11 plasma samples collected after HDM (median 192 mg m(-) (2) ) to determine melphalan AUC for a total of 114 patients. Binary logistic regression was used to assess whether melphalan AUC was associated with severe (≥ grade 3) oral mucositis. Multivariate Cox regression was used to assess whether melphalan AUC was significantly associated with time to progression, progression-free survival and overall survival (OS). RESULTS:Melphalan AUC ranged from 4.9 to 24.6 mg l(-1) h, median 12.84 mg l(-1) h. Melphalan AUC above the median was a risk factor for severe mucositis (HR 1.21, 95% CI 1.06, 1.38, P = 0.004) but was also associated with significantly improved overall survival (OS) (HR 0.40, 95% CI 0.20, 0.81, P = 0.001), with an estimated median survival of 8.50 years vs. 5.38 years for high vs. low AUC groups. Multivariate analysis did not identify melphalan AUC as being significantly associated with time to progression or progression-free survival. CONCLUSIONS: This large scale pharmacodynamic analysis of HDM demonstrates that high melphalan exposure is associated with improved survival, with an acceptable increase in transplant toxicity. These results suggest studies targeting a higher AUC are warranted in patients undergoing HDM and ASCT for myeloma.
Authors: A Badros; B Barlogie; E Siegel; C Morris; R Desikan; M Zangari; A Fassas; E Anaissie; N Munshi; G Tricot Journal: Br J Haematol Date: 2001-09 Impact factor: 6.998
Authors: Antonio Palumbo; Federica Cavallo; Francesca Gay; Francesco Di Raimondo; Dina Ben Yehuda; Maria Teresa Petrucci; Sara Pezzatti; Tommaso Caravita; Chiara Cerrato; Elena Ribakovsky; Mariella Genuardi; Anna Cafro; Magda Marcatti; Lucio Catalano; Massimo Offidani; Angelo Michele Carella; Elena Zamagni; Francesca Patriarca; Pellegrino Musto; Andrea Evangelista; Giovannino Ciccone; Paola Omedé; Claudia Crippa; Paolo Corradini; Arnon Nagler; Mario Boccadoro; Michele Cavo Journal: N Engl J Med Date: 2014-09-04 Impact factor: 91.245
Authors: Qaiser Bashir; Nina Shah; Simrit Parmar; Wei Wei; Gabriela Rondon; Donna M Weber; Michael Wang; Robert Z Orlowski; Sheeba K Thomas; Jatin Shah; Sofia R Qureshi; Yvonne T Dinh; Uday Popat; Paolo Anderlini; Chitra Hosing; Sergio Giralt; Richard E Champlin; Muzaffar H Qazilbash Journal: Leuk Lymphoma Date: 2011-08-24
Authors: Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz Journal: Blood Date: 2007-11-01 Impact factor: 22.113
Authors: Christa E Nath; Judith Trotman; Campbell Tiley; Peter Presgrave; Douglas Joshua; Ian Kerridge; Yiu Lam Kwan; Howard Gurney; Andrew J McLachlan; John W Earl; Ian Nivison-Smith; Lihua Zeng; Peter J Shaw Journal: Br J Clin Pharmacol Date: 2016-04-27 Impact factor: 4.335
Authors: Gunjan L Shah; Heather Landau; Dory Londono; Sean M Devlin; Satyajit Kosuri; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; David J Chung; Guenther Koehne; Suresh C Jhanwar; Ola Landgren; Ross Levine; Sergio A Giralt Journal: Leuk Lymphoma Date: 2017-01-12
Authors: Kana Mizuno; Min Dong; Tsuyoshi Fukuda; Sharat Chandra; Parinda A Mehta; Scott McConnell; Elias J Anaissie; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2018-05 Impact factor: 6.447
Authors: Liusheng Huang; Vincent Cheah; Danna Chan; Florence Marzan; Christopher C Dvorak; Francesca T Aweeka; Janel Long-Boyle Journal: Cancer Chemother Pharmacol Date: 2019-02-13 Impact factor: 3.333
Authors: Y K Cho; D W Sborov; M Lamprecht; J Li; J Wang; E M Hade; Y Gao; K Tackett; N Williams; D M Benson; Y A Efebera; A E Rosko; S M Devine; M Poi; C C Hofmeister; M A Phelps Journal: Clin Pharmacol Ther Date: 2017-05-26 Impact factor: 6.875